Microchip Beats Q4 Guidance, But Balance Sheet Risk Remains Elevated

What happened

Microchip Technology reported Q4 net sales of $1.311B, beating guidance and up 35% YoY, signaling a cyclical recovery is underway. The company’s 9-point restructuring plan is progressing, with a book-to-bill of 1.06 and distributor inventory days declining to 27. However, near-term financial strain persists: net debt/EBITDA stands at 4.7x and interest coverage is a thin 0.38x, leaving little room for error. The Q4 beat reflects strong demand normalization, but the P&L benefits from the Tempe Fab 2 closure will not materialize until the June 2026 quarter. While the revenue trajectory is encouraging, the balance sheet remains fragile, and the company must continue to deleverage and expand margins to justify a higher multiple.

Implication

Investors should remain on the sidelines until net debt/EBITDA trends below 3.5x and interest coverage exceeds 2x. The $1.311B beat suggests demand is normalizing, but the 4.7x net debt/EBITDA and 0.38x coverage ratios indicate the company is not out of the woods. The Q4 results support the stabilization view from the DeepValue report but do not alter the WAIT stance given the thin interest coverage and reliance on cost savings that have yet to hit the P&L. A sustained book-to-bill above 1.05 and further declines in distributor inventory days could lead to an upgrade to POSSIBLE BUY, but for now, patience is warranted.

Thesis delta

The Q4 beat is the first material upside surprise in recent quarters, validating the normalization narrative. However, it does not change the fundamental risk profile: leverage remains high and interest coverage dangerously low. The thesis shifts from 'wait for any recovery signs' to 'recovery is underway but balance sheet constraints limit upside until margins improve and debt is reduced.'